Analysts Set Valneva SE Sponsored ADR (NASDAQ:VALN) Target Price at $11.98

Valneva SE Sponsored ADR (NASDAQ:VALN) has been assigned an average rating of “Hold” from the five analysts that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $11.9750.

A number of equities research analysts have weighed in on the stock. The Goldman Sachs Group cut shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price objective on the stock. in a report on Wednesday. Wall Street Zen cut shares of Valneva to a “strong sell” rating in a report on Saturday. Finally, Guggenheim set a $11.00 price objective on shares of Valneva in a report on Thursday, April 16th.

Institutional Investors Weigh In On Valneva

A number of institutional investors have recently made changes to their positions in the company. XTX Topco Ltd purchased a new stake in shares of Valneva during the fourth quarter valued at approximately $94,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Valneva during the fourth quarter valued at approximately $44,000. JPMorgan Chase & Co. purchased a new stake in shares of Valneva during the third quarter valued at approximately $124,000. VSM Wealth Advisory LLC grew its holdings in shares of Valneva by 125.0% during the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after buying an additional 5,000 shares during the last quarter. Finally, Marex Group plc purchased a new stake in shares of Valneva during the second quarter valued at approximately $64,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Price Performance

Shares of VALN opened at $5.50 on Wednesday. The stock has a market cap of $473.61 million, a PE ratio of -3.48 and a beta of 1.97. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.85 and a current ratio of 2.38. Valneva has a fifty-two week low of $5.15 and a fifty-two week high of $12.25. The firm’s 50-day simple moving average is $8.46 and its two-hundred day simple moving average is $9.02.

Valneva (NASDAQ:VALN) last announced its quarterly earnings data on Sunday, February 15th. The company reported ($0.68) earnings per share for the quarter. The business had revenue of $55.92 million during the quarter. Valneva had a negative return on equity of 76.81% and a negative net margin of 67.64%. Analysts anticipate that Valneva will post -0.81 earnings per share for the current fiscal year.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.